Delia A. Deschaine, Member of the Firm in the Health Care & Life Sciences practice, in the firm’s Washington, DC, office, was quoted in HBW Insight, in “Science Board Meeting Could Launch US Toward Lawful Hemp Use, or Extend Market Limbo,” by Malcolm Spicer. (Read the full version – subscription required.)
Following is an excerpt:
Questions FDA is asking advisors and the public could generate answers propelling it toward determining whether hemp use in supplements should be lawful with a waiver of its prohibition against using ingredients studied or approved as a drug; or, the answers could stop the FDA in its feet. …
“It’s worth noting that FDA has not closed the public docket that it opened in 2019 (and reopened indefinitely in 2020) for interested parties to submit data relevant to this decision. Therefore, although not definitive, this certainly suggests that FDA may not be ready to move forward,” said Delia Ann Deschaine, a partner at Epstein Becker & Green P.C. in Washington.